Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosmolisib in advanced hematologic malignancies
NCT04018248Phase 1Completed
- Sponsor
- Boryung
- Start
- Apr 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of bosmolisib in B cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 5 more (2 arms), sponsored by Boryung. Primary endpoints: Maximum Tolerated Dose and Recommended Dose for Expansion and Number of participants with adverse events. Started Apr 2020; status: completed.
02
Drugs
bosmolisib
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04018248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018248.